Mitek Announces Schedule of Investor Conferences for May 2016

SAN DIEGO, May 09, 2016 (GLOBE NEWSWIRE) -- Mitek (NASDAQ: MITK) (www.miteksystems.com), a global leader in mobile capture and identity verification software solutions, today announced that it will present at the following investor conferences in May:

Needham Emerging Technology Conference

Thursday, May 19, 2016 at 10:40am ETThe Westin Grand Central Hotel, New York City

B. Riley & Company 17th Annual Investor Conference

Wednesday, May 25, 2016 at 12:00pm PTLoews Hollywood Hotel, Los Angeles

Mitek management will present and host one-on-one meetings with investors at these conferences. Meetings can be scheduled through the firms hosting the conferences or through MKR Group, Mitek’s investor relations firm, at [email protected].

To access a live webcast or replay of the formal presentation at these conference, visit Mitek’s website: http://investors.miteksystems.com

About Mitek

Mitek (MITK) is a global leader in mobile capture and identity verification software solutions. Mitek’s ID document verification allows an enterprise to verify a user’s identity during a mobile transaction, enabling financial institutions, payments companies and other businesses operating in highly regulated markets to transact business safely while increasing revenue from the mobile channel. Mitek also reduces the friction in the mobile user experience with advanced data prefill. These innovative mobile solutions are embedded into the apps of more than 5,000 organizations and used by tens of millions of consumers daily for new account opening, insurance quoting, mobile check deposit and more. Learn more at www.miteksystems.com. (MITK-F)

Mitek Contact :

MKR Group Investor Relations
Todd Kehrli or Jim Byers
Phone: 323-468-2300
[email protected]

You May Also Be Interested In

• Needham Starts Faeth Therapeutics (FTH) at Buy
• AM Best Places Credit Ratings of At-Bay Specialty Insurance Company Under Review With Positive Implications Following Announced Acquisition
• VERAXA Biotech AG (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision